BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 37883165)

  • 1. The role of cryopreservation techniques in manufacturing, transport, and storage of Car-T therapy products.
    Jandova M; Stacey GN; Lanska M; Gregor I; Rozsivalova P; Bekova L; Duchacova ZW; Belada D; Radocha J; Mericka P; Fuller B
    Cryo Letters; 2023; 44(3):123-133. PubMed ID: 37883165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advantages of high cell concentration prior to cryopreservation of initial leukapheresis in CAR-T cell therapy.
    Carbonell D; Monsalvo S; Catalá E; Pérez-Corral A; Villegas C; Falero C; Ruano G; Martinez M; Kwon M; Muñoz-Martínez C; Díez-Martín JL; Gayoso J; Anguita J
    Blood Transfus; 2024 May; 22(3):239-245. PubMed ID: 38063787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishment and validation of in-house cryopreserved CAR/TCR-T cell flow cytometry quality control.
    Cai Y; Prochazkova M; Jiang C; Song HW; Jin J; Moses L; Gkitsas N; Somerville RP; Highfill SL; Panch S; Stroncek DF; Jin P
    J Transl Med; 2021 Dec; 19(1):523. PubMed ID: 34952597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Manufacturing chimeric antigen receptor T cells from cryopreserved peripheral blood cells: time for a collect-and-freeze model?
    Palen K; Zurko J; Johnson BD; Hari P; Shah NN
    Cytotherapy; 2021 Nov; 23(11):985-990. PubMed ID: 34538575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autologous cryopreserved leukapheresis cellular material for chimeric antigen receptor-T cell manufacture.
    Tyagarajan S; Schmitt D; Acker C; Rutjens E
    Cytotherapy; 2019 Dec; 21(12):1198-1205. PubMed ID: 31837735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation of cryopreserved chimeric antigen receptor T cells for the locoreogional delivery to the neural axis.
    Akel S; Poston L; Park JJ; Schoultz SB; Alloush L; Zheng F; Zhou S; Lockey T; Willis C; DeRenzo C; Gottschalk S
    Cytotherapy; 2023 Nov; 25(11):1149-1154. PubMed ID: 37676217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developing lisocabtagene maraleucel chimeric antigen receptor T-cell manufacturing for improved process, product quality and consistency across CD19
    Teoh J; Brown LF
    Cytotherapy; 2022 Sep; 24(9):962-973. PubMed ID: 35610089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement of in vitro potency assays by a resting step for clinical-grade chimeric antigen receptor engineered T cells.
    Wang L; Gong W; Wang S; Neuber B; Sellner L; Schubert ML; Hückelhoven-Krauss A; Kunz A; Gern U; Michels B; Hinkelbein M; Mechler S; Richter P; Müller-Tidow C; Schmitt M; Schmitt A
    Cytotherapy; 2019 May; 21(5):566-578. PubMed ID: 30910382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Cryopreservation on Autologous Chimeric Antigen Receptor T Cell Characteristics.
    Panch SR; Srivastava SK; Elavia N; McManus A; Liu S; Jin P; Highfill SL; Li X; Dagur P; Kochenderfer JN; Fry TJ; Mackall CL; Lee D; Shah NN; Stroncek DF
    Mol Ther; 2019 Jul; 27(7):1275-1285. PubMed ID: 31178392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical outcomes of fresh versus cryopreserved CD19-directed chimeric antigen receptor T cells in non-Hodgkin lymphoma patients.
    Su T; Ying Z; Lu XA; He T; Song Y; Wang X; Ping L; Xie Y; Tu M; Liu G; Qi F; Ding Y; Jing H; Zhu J
    Cryobiology; 2020 Oct; 96():106-113. PubMed ID: 32721392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishment of a New Cryopreservation Solution for Chimeric Antigen Receptor T Cells.
    Tang Q; Gu L; Zhou B; Shi J; Wu H; Zhu H; Xu Y; Zhang T
    Biopreserv Biobank; 2022 Dec; 20(6):567-574. PubMed ID: 35294840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Manufacturing chimeric antigen receptor T cells: issues and challenges.
    Roddie C; O'Reilly M; Dias Alves Pinto J; Vispute K; Lowdell M
    Cytotherapy; 2019 Mar; 21(3):327-340. PubMed ID: 30685216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of cryopreservation on CAR T production and clinical response.
    Brezinger-Dayan K; Itzhaki O; Melnichenko J; Kubi A; Zeltzer LA; Jacoby E; Avigdor A; Shapira Frommer R; Besser MJ
    Front Oncol; 2022; 12():1024362. PubMed ID: 36276077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cryopreservation of NK and T Cells Without DMSO for Adoptive Cell-Based Immunotherapy.
    Yao X; Matosevic S
    BioDrugs; 2021 Sep; 35(5):529-545. PubMed ID: 34427899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishing a robust chimeric antigen receptor T-cell therapy program in Australia: the Royal Prince Alfred Hospital experience.
    Velickovic ZM; Rasko JEJ
    Cytotherapy; 2022 Jan; 24(1):45-48. PubMed ID: 34521574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cryopreserved leukapheresis material can be transferred from controlled rate freezers to ultracold storage at warmer temperatures without affecting downstream CAR-T cell culture performance and in-vitro functionality.
    Wei J; Chaney K; Shim WJ; Chen H; Leonard G; O'Brien S; Liu Z; Jiang J; Ulrey R
    Cryobiology; 2024 Mar; 115():104889. PubMed ID: 38513998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and Validation of a Good Manufacturing Process for IL-4-Driven Expansion of Chimeric Cytokine Receptor-Expressing CAR T-Cells.
    van Schalkwyk MCI; van der Stegen SJC; Bosshard-Carter L; Graves H; Papa S; Parente-Pereira AC; Farzaneh F; Fisher CD; Hope A; Adami A; Maher J
    Cells; 2021 Jul; 10(7):. PubMed ID: 34359966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality risk management of the chimeric antigen receptor T cell pharmaceutical circuit in one of the first qualified European centers.
    Talarmin C; Kerob S; Cartier F; Madelaine I; Mukenyi S; Schwartz E; Boissel N; Baruchel A; Thieblemont C; Parquet N; Brignier A; Lesprit E; Desproges A; Magdelonnette L; Larghero J; Mebarki M
    Cytotherapy; 2020 Dec; 22(12):792-801. PubMed ID: 32732084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GMP-Compliant Manufacturing of NKG2D CAR Memory T Cells Using CliniMACS Prodigy.
    Fernández L; Fernández A; Mirones I; Escudero A; Cardoso L; Vela M; Lanzarot D; de Paz R; Leivas A; Gallardo M; Marcos A; Romero AB; Martínez-López J; Pérez-Martínez A
    Front Immunol; 2019; 10():2361. PubMed ID: 31649672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CAR-T manufactured from frozen PBMC yield efficient function with prolonged
    Abraham-Miranda J; Menges M; Atkins R; Mattie M; Kanska J; Turner J; Hidalgo-Vargas MJ; Locke FL
    Front Immunol; 2022; 13():1007042. PubMed ID: 36225930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.